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Abstract
Background: Etomidate is a commonly used sedative in intravenous anesthesia. The aim of this study was to
compare the effects of various etomidate doses administered by continuous infusion on adrenal function in dogs
under general anesthesia.
Methods: Thirty-six healthy adult male dogs were randomly divided into six groups. Sodium pentobarbital alone was
administered to the control group (group C); five experimental groups (E1, E2, E3, E4, and E5) were also given etomidate
at doses of 10, 15, 20, 25, and 30 μg · kg−1 · min−1, respectively, to maintain anesthesia. Heart rate (HR), mean arterial
pressure (MAP), and bispectral index (BIS) were monitored. Serum cortisol, aldosterone, adrenaline, and noradrenaline
levels were measured, and HR, MAP, and BIS values recorded, before intubation (T0), and at 1 h, 2 h, and 3 h after
intubation (T1–3).
Results: Cortisol and aldosterone levels in groups E1–5 decreased as the doses and times of continuous infusion of
etomidate increased. The cortisol level was significantly decreased compared with baseline at T3 in group E1 and at T1–3
in groups E2–5 (P < 0.05). Compared with the corresponding levels in group C, cortisol levels were significantly lower
than T0 values at T3 in group E1 and at T1–3 in groups E2–5 (P < 0.05). The aldosterone level was significantly lower at T3
in group E2 and at T1–3 in groups E3–5 (P < 0.05). Significant reductions in cortisol levels at T2–3 in group E2 and at T1–3 in
groups E3–5 compared with group C were also observed (P < 0.05). The plasma adrenaline and noradrenaline levels, HR,
MAP, and BIS in groups E1–5 were within the normal range at the different times and with the different doses (P > 0.05).
Conclusions: Cortisol and aldosterone levels decreased with time and continuous infusion of etomidate; there were no
significant changes in adrenaline and noradrenaline levels, HR, MAP, and BIS in any group.
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Background
Etomidate is a short-acting sedative with rapid onset of
effects that is commonly used for inducing short-term
anesthesia prior to intubation in patients. Advantages of
this general anesthetic agent include rapid recovery of
consciousness and minimal influence on tidal volume
and systemic pressure. It is safe and especially suitable
for patients with coronary heart disease, hypertension,
old age, or shock [1, 2]. Etomidate is an intravenous in-
duction agent that is associated with hemodynamic sta-
bility following administration [3, 4]. Compared with
propofol, etomidate shows greater hemodynamic stability
after induction of anesthesia, and may be preferred over
propofol for general anesthesia [5]. Etomidate should be
considered for induction of anesthesia in cardiac surgery
patients [5, 6]. One of the most common—but impor-
tant—side effects of this drug is the suppression of steroid
production by the reversible inhibition of the 11-beta-
hydroxylase enzyme [3]. Etomidate is rarely used to main-
tain anesthesia because of this adrenal suppression [7].
However, some studies have reported that when adminis-
tered to induce anesthesia, the suppression is transient,
and others have noted no significant inhibitory effect on
adrenocortical function in patients with severe sepsis or
septic shock [8–10]. The pros and cons of etomidate
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continue to be discussed, and its use remains controversial
[11–13]. The objective of this study was to evaluate the ef-
fects of continuous infusion of various doses of etomidate
on adrenal function in dogs. Therefore, applications and
disadvantages of etomidate relying on disputed, especially
whether they have a significant effect on adrenal function.




All procedures were conducted in accordance with the
rules and regulations of the Subcommittee on Research
Animal Care at Zunyi Medical College. Thirty-six
healthy adult male mongrel dogs of the same breed,
eight to 12 months of age, and weighing 10 ± 2.5 kg were
used for the study. The dogs were fasted 12 h prior to
the experiment and were randomly divided into six
groups. Dogs in the control group (group C) were anes-
thetized with sodium pentobarbital only. Dogs in experi-
mental groups (E1, E2, E3, E4, and E5) underwent
induction of anesthesia and were intubated using sodium
pentobarbital and then maintained under anesthesia for
3 h with a continuous infusion of etomidate at doses of
10, 15, 20, 25, and 30 μg · kg−1 · min−1, respectively. This
study was carried out in strict accordance with the rec-
ommendations in the Guide for the Care and Use of La-
boratory Animals of the National Institutes of Health.
The animal use protocol has been reviewed and ap-
proved by the Institutional Animal Care and Use Com-
mittee (IACUC) of Zunyi Medical College.
Medicines and instruments
Etomidate was obtained from Xuzhou Enhua Pharma-
ceutical Co., Ltd. (batch number: 20100430), and vecur-
onium bromide (it is no histamine release and little
effect on hemodynamics and cheap [14]) was obtained
from Zhejiang Xianju Pharmaceutical Co., Ltd. (batch
number: 100503). An RY-R type anesthesia machine was
purchased from Jiangsu Kaitai Medical Equipment Co.,
Ltd. A multi-function monitor (UT4000Fpro) was pur-
chased from Shenzhen Kaitai Industry Co., Ltd., and
UP8000 depth of anesthesia monitors were purchased
from the Shenzhen Kerui Kang Industrial Co., Ltd. The
manufacturers is GC-2010γRadio immunity counter,
University of Science and Technology of China science
and Technology Industrial Corporation.
Anesthetic methods
The dogs were pre-treated with 2.5 % sodium pentobar-
bital (25,000 μg/kg) intraperitoneally at 8:15 to 8:30 on
the procedure day, and catheters were placed in the right
femoral artery and vein. Sodium heparin (3000 μg/kg)
was infused via a central venous line, and mean arterial
pressure (MAP), heart rate (HR), and bispectral index
(BIS) were monitored. Animals were heparinized to fa-
cilitate the collection of blood samples. Group C animals
were anesthetized with 2.5 % sodium pentobarbital
(500 μg/kg) and supplemented at appropriate intervals
by intraperitoneal injection to maintain a BIS value of
40–60 (it is depth of anesthesia and close clinical
anesthesia state). In addition to sodium pentobarbital,
dogs in the five experimental groups (E1, E2, E3, E, and
E5) received infusions of etomidate at doses of 10, 15,
20, 25, and 30 μg · kg−1 · min−1, respectively, and were
maintained under anesthesia for 3 h. Respiratory param-
eters were set as follows: tidal volume, 15 mL/kg; re-
spiratory rate, 15–18 times per minute; I:E, 1:2; oxygen
flow rate, 2 L/min; and PETCO2, 4.66-5.99 kPa. Each dog
received 4–6 mL · kg−1 · h−1 Lactated Ringer’s solution IV
to maintain the central venous pressure (CVP) between
6 and 10 cmH2O. Subsequently intermittent boluses of
Table 1 Six group dogs cortisol, aldosterone concentration change and comparison n ¼ 6; x  sð Þ
Index Group T0 T1 T2 T3
Cortisol (ng/ml) C 253.73 ± 23.87 246.76 ± 16.95 247.88 ± 16.81 251.53 ± 18.62
E1 254.10 ± 22.10 247.70 ± 21.24 240.95 ± 20.71 222.72 ± 19.87*#
E2 249.25 ± 17.15 215.40 ± 19.51*# 181.32 ± 14.89*# 159.63 ± 18.47*#
E3 248.43 ± 16.99 193.33 ± 17.95*# 161.31 ± 17.43*# 120.14 ± 18.05*#
E4 249.72 ± 20.41 182.80 ± 19.14*# 148.80 ± 17.42*# 116.33 ± 10.84*#
E5 248.28 ± 23.02 165.32 ± 20.56*# 126.43 ± 16.82*# 85.69 ± 12.90*#
Aldosterone (pg/ml) C 133.93 ± 14.37 129.15 ± 18.78 124.89 ± 14.00 129.83 ± 11.23
E1 140.54 ± 19.63 134.77 ± 18.35 128.48 ± 16.74 113.81 ± 16.67
E2 135.76 ± 15.01 119.28 ± 12.01 100.98 ± 12.65# 79.70 ± 11.66*#
E3 129.61 ± 16.51 105.24 ± 15.30*# 80.98 ± 15.80*# 64.28 ± 11.88*#
E4 136.29 ± 16.52 102.07 ± 16.28*# 75.95 ± 11.34*# 59.37 ± 8.98*#
E5 128.55 ± 26.43 93.66 ± 25.79*# 69.87 ± 18.70*# 55.35 ± 13.18*#
And T0 comparison, *P < 0.05; and C group comparison,
#P < 0.05
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vecuronium bromide (50 μg/kg) were administered for
neuromuscular blockade to maintain the muscle relax-
ant. The temperature of the controlled laboratory was
23 °C and the animals’ temperature was 37–38 °C.
Observation indexes
Blood samples were collected from the right femoral
vein at time points T0 to T3 for radioimmunoassay ana-
lysis of serum cortisol, aldosterone, adrenaline, and nor-
adrenaline concentrations [15]. MAP, HR, and BIS were
recorded at the same time points. Indeed, the half-life of
serum cortisol, serum aldosterone and ACTH in human
blood is 70 min [16], 20 min [17], and 10 min [18],
respectively.
Statistical analysis
All data are reported as the mean ± SD. Statistical analyses
were performed using SPSS17.0 software. Single factor
analysis of variance was compared between groups.
Pair-wise comparisons underwent post hoc testing with
Dunnett’s t test. For all statistical analyses, P < 0.05
indicated statistical significance.
Fig. 1 Changes of several indexes with different doses (10, 15, 20, 25, and 30 μg•kg−1•min−1) at different time points (T0, T1, T2 and T3). a Changes of
cortisol with different concentrations in different groups; (b) Changes of aldosterone with different concentrations in different groups; (c) Changes of
epinephrine with different concentrations in different groups; (d) Changes of noradrenaline with different concentrations in different groups; (e)
Changes of heart rate with different concentrations in different groups; (f) Changes of mean arterial pressure with different concentrations in
different groups
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Results
Cortisol and aldosterone levels
Results are summarized in Table 1 (Fig. 1). The corti-
sol and aldosterone levels in groups E1–5 decreased as
the dose of etomidate and length of infusion time in-
creased. Compared with T0 values, the cortisol level
was significantly decreased at T3 in group E1 and at
T1–3 in groups E2–5 (P < 0.05). For example, the level
was 215.40 ± 19.51 in group E2 significantly lower
than the corresponding level (246.76 ± 16.95) in group
C. Compared with group C, cortisol was significantly
decreased relative to T0 values at T3 in group E1 and
at T1–3 in groups E2–5 (P < 0.05). The aldosterone
level was significantly decreased at T3 in group E2
and at T1–3 in groups E3–5 (P < 0.05); in comparison with
the corresponding values in group C, the aldosterone
levels were significantly lower at T2–3in group E2 and at
T1–3 in groups E3–5 (P < 0.05). Compared with the values
in group C, serum cortisol and aldosterone concentrations
in groups E1-E5 demonstrated a dose-dependent reduction
(P < 0.05) (Table 1 and Fig. 1).
Adrenaline and noradrenaline levels
Results are summarized in Table 2 (Fig. 1). The plasma
adrenaline and noradrenaline levels in groups E1–5 were
within the normal range at the different times and doses
(P > 0.05).
Hemodynamics and BIS
Results are summarized in Table 2 (Fig. 1). HR, MAP,
and BIS values in groups E1–5 were within the normal
range at the different times and doses (P > 0.05).
Table 2 The plasma epinephrine, norepinephrine concentration and HR, MAP, BIS value in six group dogs n ¼ 6; x  sð Þ
Index Group T0 T1 T2 T3
Adrenaline (pg/ml) C 43.53 ± 6.24 41.09 ± 6.91 41.29 ± 4.04 41.66 ± 4.87
E1 43.32 ± 5.85 42.28 ± 4.22 43.61 ± 4.73 43.87 ± 5.70
E2 42.65 ± 5.39 40.73 ± 3.68 40.87 ± 3.68 39.82 ± 5.02
E3 44.29 ± 5.77 44.37 ± 3.64 43.05 ± 5.72 43.87 ± 5.56
E4 43.50 ± 5.89 41.49 ± 5.31 41.05 ± 4.71 41.66 ± 4.72
E5 44.73 ± 7.10 45.08 ± 4.89 43.73 ± 4.98 43.96 ± 5.26
Noradrenaline (pg/ml) C 288.86 ± 36.37 277.90 ± 40.30 291.46 ± 23.99 281.36 ± 29.27
E1 292.10 ± 32.97 297.13 ± 25.21 285.51 ± 29.30 291.17 ± 32.93
E2 300.00 ± 34.08 301.12 ± 24.32 298.77 ± 22.61 297.21 ± 30.30
E3 300.43 ± 32.74 295.03 ± 26.47 290.53 ± 31.35 297.63 ± 24.39
E4 306.56 ± 33.67 300.71 ± 33.29 305.37 ± 21.80 307.97 ± 27.67
E5 292.54 ± 27.16 288.37 ± 16.86 296.69 ± 30.30 287.81 ± 12.12
HR (Times/min) C 174.50 ± 7.48 178.17 ± 11.6 169.00 ± 16.82 163.33 ± 16.53
E1 168.00 ± 18.17 169.50 ± 14.99 165.00 ± 11.49 162.00 ± 7.54
E2 172.33 ± 9.25 169.50 ± 9.14 170.00 ± 11.45 172.67 ± 13.71
E3 165.33 ± 8.21 168.33 ± 6.83 162.83 ± 8.38 167.67 ± 7.42
E4 161.83 ± 15.15 164.33 ± 9.95 157.33 ± 14.15 154.67 ± 12.00
E5 171.00 ± 13.76 171.00 ± 17.82 172.00 ± 14.30 171.33 ± 14.68
MAP (mmHg) C 138.00 ± 16.57 138.67 ± 12.79 139.00 ± 12.77 134.17 ± 12.70
E1 129.33 ± 11.04 129.83 ± 6.74 128.83 ± 9.17 128.83 ± 5.04
E2 125.83 ± 12.86 129.83 ± 12.92 131.50 ± 11.31 131.17 ± 10.42
E3 131.50 ± 9.48 131.83 ± 6.68 134.67 ± 7.23 133.33 ± 8.31
E4 128.33 ± 11.22 128.50 ± 14.36 130.17 ± 12.35 127.83 ± 11.39
E5 138.50 ± 8.34 137.67 ± 9.00 135.50 ± 5.86 139.00 ± 9.14
BIS C 47.67 ± 3.33 47.50 ± 1.76 48.17 ± 2.93 46.83 ± 3.66
E1 46.50 ± 5.05 47.50 ± 4.76 46.50 ± 4.59 48.17 ± 5.49
E2 43.83 ± 3.06 45.83 ± 4.12 44.50 ± 2.81 45.00 ± 3.10
E3 47.33 ± 3.72 46.67 ± 3.39 49.33 ± 3.39 49.83 ± 5.04
E4 48.00 ± 2.61 45.17 ± 3.66 46.83 ± 3.06 43.83 ± 2.48
E5 45.33 ± 4.10 44.83 ± 2.86 44.17 ± 3.13 44.00 ± 2.45
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Discussion
Etomidate was introduced into clinical practice in 1972,
and initial reports of its use in humans emerged in the
clinical literature soon afterward [19]. Etomidate is the
only imidazole among the general anesthesia induction
drugs, and it has the most favorable therapeutic index for
single bolus administration [4, 6]. Etomidate induces less
apnea than barbiturates or propofol, does not cause
histamine release, and very rarely causes allergic reactions
[5, 20]. Because of its remarkably benign hemodynamic
effects, etomidate has proven useful for general anesthetic
induction in patients undergoing cardiac surgery and
those with poor cardiac function [21, 22]. The major
molecular targets mediating the anesthetic effects of
etomidate in the central nervous system are specific
γ-aminobutyric acid type A receptor subtypes. It also
produces a unique toxicity among anesthetic drugs:
inhibition of adrenal steroid synthesis that far outlasts
its hypnotic action [20]. Adrenal cortical inhibition by
etomidate has received a great deal of attention and
significantly limits its use as both an anesthetic and a
sedative [23, 24]. A vigorous debate regarding the use
of etomidate for intubation continues [25, 26].
The adrenal cortex secretes cortisol and aldosterone,
and their concentrations may reflect adrenocortical
function. Because cortisol has a circadian rhythm, we in-
duced anesthesia at the same time every day during our
study. We designed our experiments which references
for the clinical dose range 10–20 μg · kg−1 · min−1of
etomidate and dog doses equivalent to the human
1.88 times [20]. The cortisol and aldosterone levels in
groups E1–5 demonstrated time- and dose-dependent
reductions with the continuous infusion of etomidate.
Our results therefore show that intravenous infusion
of etomidate can inhibit adrenal cortical functions. The
adrenal medulla secretes epinephrine and norepinephrine.
Catecholamines are important indicators of the stress
response and have obvious correlations with hemodynamic
changes. In our study, plasma epinephrine and nor-
epinephrine concentrations stayed within normal
ranges in the experimental dogs and there were no
statistically significant differences at the various times in
the control group. HR and MAP remained within normal
ranges as etomidate doses and times increased. Etomidate
anesthesia does not have a significant effect on periopera-
tive epinephrine and norepinephrine levels. Etomidate,
used as a continuous infusion at 10–30 μg · kg−1 · min−1
for colonoscopy can maintain a good depth of anesthesia
and results in faster recovery than propofol-remifentanil
sedation [27]. Etomidate also can maintain good clinical
anesthesia depth (BIS value) as the dose increases. In
our study, BIS values showed minimal change with
different doses of etomidate, probably because of the lack
of surgical stimulation and the use of a muscle relaxant.
Meanwhile, experiments were carried out under iso-
thermal conditions which did not affect the results.
Although the altered temperature may affect the depth of
anesthesia, we carefully monitored the temperature of
dogs during the experiment.
Our study used continuous infusion of different doses of
etomidate in dogs and determined that serum cortisol and
aldosterone levels were decreased as the time and doses of
etomidate infusion increased, but there were no significant
changes in adrenaline, noradrenaline, or hemodynamic
values. As etomidate administered at 10 μg · kg−1 · min−1
for 3 h had minimal effect on adrenocortical and adrenal
medulla function, use of etomidate at this dose may be
safe for anesthesia maintenance.
We did not perform ACTH stimulation tests in this
experiment, mainly because pre-anesthetic testing in the
study dogs revealed normal adrenal function. However,
this is a limitation of our experiment.
Conclusion
In summary, the study showed that cortisol and aldos-
terone levels decreased with time and continuous infusion
of various etomidate in dogs under general anesthesia;
there were no significant changes in adrenaline and
noradrenaline levels, HR, MAP, and BIS in any group.
These results provide reference for clinical application.
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